123 related articles for article (PubMed ID: 8708979)
1. Effect of alginate and alginate-cimetidine combination therapy on stimulated postprandial gastro-oesophageal reflux.
Washington N; Denton G
J Pharm Pharmacol; 1995 Nov; 47(11):879-82. PubMed ID: 8708979
[TBL] [Abstract][Full Text] [Related]
2. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension.
Washington N; Greaves JL; Iftikhar SY
Aliment Pharmacol Ther; 1992 Oct; 6(5):579-88. PubMed ID: 1420749
[TBL] [Abstract][Full Text] [Related]
3. Patterns of food and acid reflux in patients with low-grade oesophagitis--the role of an anti-reflux agent.
Washington N; Steele RJ; Jackson SJ; Washington C; Bush D
Aliment Pharmacol Ther; 1998 Jan; 12(1):53-8. PubMed ID: 9692701
[TBL] [Abstract][Full Text] [Related]
4. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
5. Algitec: an illogical combination?
Drug Ther Bull; 1990 Sep; 28(19):76. PubMed ID: 2131223
[No Abstract] [Full Text] [Related]
6. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
7. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
8. The suppression of gastro-oesophageal reflux by alginates.
Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
10. The comparative bioavailability of cimetidine-alginate treatments.
Britton AM; Nichols JD; Draper PR
J Pharm Pharmacol; 1991 Feb; 43(2):122-3. PubMed ID: 1672897
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
[TBL] [Abstract][Full Text] [Related]
12. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
14. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; Smout AJ; Thomas E; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1585-91; quiz e90. PubMed ID: 23669304
[TBL] [Abstract][Full Text] [Related]
15. In-vivo anti-reflux and raft properties of alginates.
Lambert JR; Korman MG; Nicholson L; Chan JG
Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
Chatfield S
Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
[TBL] [Abstract][Full Text] [Related]
17. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
19. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
[TBL] [Abstract][Full Text] [Related]
20. Combination of cimetidine and alginic acid: an improvement in the treatment of oesophageal reflux disease. Cooperative Oesophageal Group.
Gut; 1991 Jul; 32(7):819-22. PubMed ID: 1855691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
